Hengeler Mueller and Latham have advised on the flotation of biotechnology company Epigenomics, securing roles on one of this year’s most closely-watched national deals.

The Berlin-based biotech group had its shares listed on the Frankfurt stock exchange on 19 July, valuing it at € 41.6m (£27.7m). The deal was Germany’s fourth IPO this year and the first in the depressed biotech sector since the collapse of Germany’s capital markets in 2001 led to the shutting down of the Neuer Markt.